following a full submission:
ticagrelor 60mg film-coated tablets (Brilique®) is not recommended for use within NHS Scotland.
Indication under review: co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.
A large, phase 3, randomised, double-blind study in a high risk population who had suffered a myocardial infarction in the previous one to three years demonstrated that the addition of ticagrelor to aspirin significantly reduced the risk of ischaemic events (a composite of cardiovascular death, myocardial infarction and stroke).
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
|Drug Name:||ticagrelor (Brilique)|
|SMC Drug ID:||1224/17|
|Manufacturer:||AstraZeneca UK Ltd|
|Indication:||Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.|
|Sub Category:||2.9 Antiplatelet drugs|
|Submission Type:||Full submission|
|Date Advice Published:||10 April 2017|